Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (TRC105)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01326481
Recruitment Status : Completed
First Posted : March 31, 2011
Last Update Posted : February 7, 2018
Roswell Park Cancer Institute
United States Department of Defense
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2014
  Study Completion Date : December 2014